OBJECTIVES: To evaluate response, time to progression and survival of patients with limited disease (LD) small cell carcinoma of the bladder (SCCB) treated with sequential chemoradiation in analogy to LD small cell lung cancer (SCLC). METHODS: Of 42 patients with SCCB treated at our institution between 1993 and 2007, 17 with LD SCCB treated with chemoradiation were identified and retrospectively analysed. LD was defined as any pT, cN0-1, cM0. SCCB was defined according to WHO criteria. All patients had platinum-based chemotherapy after transurethral resection (TUR) prior to local radiotherapy with 56-70 Gy. RESULTS: Sixteen patients were male, 1 female. Median age was 62 years. Median overall survival is 32.5 months. All had a clinical local response (15 CR, 2 PR). Systemic progression occurred in 8 (47%) with a median time to progression of 6 months (range 1-16 months), 8 died with a median survival of 17.5 months. Currently, 7 are free of disease (FOD) including 2 at 80 and 87 months. Four (23.5%) had a local recurrence as late as 43 and 50 months; 3 required a salvage cystectomy. CONCLUSIONS: Clinical results of sequential chemoradiation for LD SCCB are comparable to contemporary series of LD SCCB treated with cystectomy and upfront or adjuvant chemotherapy. Long-term survival of more than 5 years after chemoradiation can be achieved. The risk of local recurrence is lower than reported, but late recurrences occur. These data suggest that bladder sparing with systemic chemotherapy and local control by radiotherapy should be further investigated in this aggressive disease.
OBJECTIVES: To evaluate response, time to progression and survival of patients with limited disease (LD) small cell carcinoma of the bladder (SCCB) treated with sequential chemoradiation in analogy to LD small cell lung cancer (SCLC). METHODS: Of 42 patients with SCCB treated at our institution between 1993 and 2007, 17 with LD SCCB treated with chemoradiation were identified and retrospectively analysed. LD was defined as any pT, cN0-1, cM0. SCCB was defined according to WHO criteria. All patients had platinum-based chemotherapy after transurethral resection (TUR) prior to local radiotherapy with 56-70 Gy. RESULTS: Sixteen patients were male, 1 female. Median age was 62 years. Median overall survival is 32.5 months. All had a clinical local response (15 CR, 2 PR). Systemic progression occurred in 8 (47%) with a median time to progression of 6 months (range 1-16 months), 8 died with a median survival of 17.5 months. Currently, 7 are free of disease (FOD) including 2 at 80 and 87 months. Four (23.5%) had a local recurrence as late as 43 and 50 months; 3 required a salvage cystectomy. CONCLUSIONS: Clinical results of sequential chemoradiation for LD SCCB are comparable to contemporary series of LD SCCB treated with cystectomy and upfront or adjuvant chemotherapy. Long-term survival of more than 5 years after chemoradiation can be achieved. The risk of local recurrence is lower than reported, but late recurrences occur. These data suggest that bladder sparing with systemic chemotherapy and local control by radiotherapy should be further investigated in this aggressive disease.
Authors: B E Johnson; J D Bridges; M Sobczeck; J Gray; R I Linnoila; A F Gazdar; L Hankins; S M Steinberg; M Edison; J N Frame; H Pass; J Nesbitt; D Holden; J L Mulshine; E Glatstein; D C Ihde Journal: J Clin Oncol Date: 1996-03 Impact factor: 44.544
Authors: R Bastús; J M Caballero; G González; P Borrat; J Casalots; G Gomez de Segura; L I Martí; J Ristol; L Cirera Journal: Eur Urol Date: 1999-04 Impact factor: 20.096
Authors: B E Johnson; J Grayson; R W Makuch; R I Linnoila; M J Anderson; M H Cohen; E Glatstein; J D Minna; D C Ihde Journal: J Clin Oncol Date: 1990-03 Impact factor: 44.544
Authors: D J Grignon; J Y Ro; A G Ayala; D T Shum; N G Ordóñez; C J Logothetis; D E Johnson; B Mackay Journal: Cancer Date: 1992-01-15 Impact factor: 6.860
Authors: Patricia Moretto; Lori Wood; Urban Emmenegger; Normand Blais; Som Dave Mukherjee; Eric Winquist; Eric Charles Belanger; Robert Macrae; Alexander Balogh; Ilias Cagiannos; Wassim Kassouf; Peter Black; Piotr Czaykowski; Joel Gingerich; Scott North; Scott Ernst; Suzanne Richter; Srikala Sridhar; M Neil Reaume; Denis Soulieres; Andrea Eisen; Christina M Canil Journal: Can Urol Assoc J Date: 2013 Jan-Feb Impact factor: 1.862
Authors: Marco Moschini; David D'Andrea; Stephan Korn; Yasin Irmak; Francesco Soria; Eva Compérat; Shahrokh F Shariat Journal: Nat Rev Urol Date: 2017-09-12 Impact factor: 14.432
Authors: Siobhan P Lynch; Yu Shen; Ashish Kamat; H Barton Grossman; Jay B Shah; Randall E Millikan; Colin P Dinney; Arlene Siefker-Radtke Journal: Eur Urol Date: 2012-04-17 Impact factor: 20.096